ArticleMedical science monitor : international medical journal of experimental and clinical research2022
Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 58 citations in OpenAlex.
- Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18-55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial.The Journal of infectious diseases · 2026Trial
- Engineering a Novel Bacterial Encapsulin for Programmable Surface Functionalization: From Single-Target to Mosaic Nanovaccines.bioRxiv : the preprint server for biology · 2026Article
- A continuous viral vaccine biomanufacturing platform utilizing multiple bioreactor configurations.Journal of biological engineering · 2026Article
- Article
- From bench to bedside: Unveiling the background and benefits of nanovaccines tested in clinics.Asian journal of pharmaceutical sciences · 2026Review
- Yeast-Based Vaccine Platforms: Applications and Key Insights from the COVID-19 Era.Biomolecules · 2026Review
- A phase 1, single-center, randomized, dose finding study to evaluate the safety, tolerability, and immunogenicity of a prophylactic COVID-19 pDNA vaccine after single ascending doses in healthy adults.Frontiers in medicine · 2026Article
- Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies.Microbiology and molecular biology reviews : MMBR · 2025Review
- Leaf Saponins ofPharmaceutics · 2025Review
- Saudi Heart Association Position Statement on Adult Vaccinations for Patients With Cardiovascular Diseases.Journal of the Saudi Heart Association · 2025Article
- Universal subunit vaccine protects against multiple SARS-CoV-2 variants and SARS-CoV.NPJ vaccines · 2024Article
- SARS-CoV-2 Vaccine-Elicited Immunity after B Cell Depletion in Multiple Sclerosis.ImmunoHorizons · 2024Article
- Editorial: Global Health Concerns as Vaccine-Preventable Infections Including SARS-CoV-2 (JN.1), Influenza, Respiratory Syncytial Virus (RSV), and Measles Continue to Rise.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Review
- Global Emergence of SARS-CoV2 Infection and Scientific Interventions to Contain its Spread.Current protein & peptide science · 2024Review
- A trimeric spike-based COVID-19 vaccine candidate induces broad neutralization against SARS-CoV-2 variants.Human vaccines & immunotherapeutics · 2023Article
- Nanoparticles and Antiviral Vaccines.Vaccines · 2023Review
- Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period.Signal transduction and targeted therapy · 2023Review
- Article
- Ginseng Polysaccharide Enhances the Humoral and Cellular Immune Responses to SARS-CoV-2 RBD Protein Subunit Vaccines.Vaccines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Nuvaxovid™ (NVX-CoV2373) Novavax vaccine is a recombinant spike (S) protein nanoparticle vaccine combined with the Matrix-M adjuvant. On December 20, 2021, the European Commission of the European Union (EU) granted conditional marketing authorization for the Nuvaxovid™ (NVX-CoV2373) Novavax vaccine, following recommendations from the European Medicines Agency (EMA). On February 3, 2022, this vaccine was granted conditional marketing authorization (CMA) in Great Britain by the Medicines and Healthcare Products Regulatory Agency (MHRA) for use in individuals ≥18 years. The two vaccine components elicit both B-lymphocyte and T-lymphocyte immune responses to the S protein of SARS-CoV-2. The full-length S protein in this vaccine has common epitopes that could protect against all the SARS-CoV-2 viral variants. Also, the vaccine is stable and has a shelf life of 9 months when stored at standard refrigerated temperatures of between 2-8°C. This Editorial aims to present an update on the first approval of a protein-based adjuvanted vaccine for SARS-CoV-2, Nuvaxovid (NVX-CoV2373) from Novavax, and why it is such a significant development at this time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.